Analysts think MURA stock price could increase by 301%
Jun 14, 2024, 6:32 AM
-6.95%
What does MURA do
Mural Oncology PLC, an Ireland-based clinical-stage biotechnology company, specializes in developing cytokine-based immunotherapies for cancer, using a protein engineering platform to target diseases with limited treatment options. Their portfolio features therapies like Nemvaleukin alfa, a modified IL-2 designed to reduce toxicity and selectively activate key immune cells, alongside a tumor-targeted IL-12 program.
3 analysts think MURA stock price will increase by 300.60%. The current median analyst target is $13.26 compared to a current stock price of $3.31. The lowest analysts target is $13.13 and the highest analyst target is $13.65.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
